A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal
Giuseppe Floris(KU Leuven), Patrick Schöffski(KU Leuven), Haifu Li(Brigham and Women's Hospital), Christophe M. Deroose(KU Leuven), Jasmien Wellens(Brigham and Women's Hospital), Agnieszka Woźniak(VIB-KU Leuven Center for Cancer Biology), Peter Vermaelen(Brigham and Women's Hospital), Raf Sciot(KU Leuven), Lori S. Friedman, Maria Dêbiec‐Rychter(Center for Human Genetics), Jonathan A. Fletcher(Harvard University), Thomas Van Looy(KU Leuven)
Cited by 69
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2016|766
TPM3-ALK and TPM4-ALK Oncogenes in Inflammatory Myofibroblastic Tumors
|American Journal Of Pathology|2000|716